We are live on ! Find out more
PCM

Pathway Capital Management Portfolio holdings

AUM $23.9M
1-Year Est. Return 81.94%
This Fund
S&P 500
This Quarter Est. Return
+42.12%
1 Year Est. Return
+81.94%
3 Year Est. Return
+629.07%
5 Year Est. Return
+429.81%
10 Year Est. Return
–
AUM
$1.28M
AUM Growth
-$111M
Cap. Flow
-$111M
Cap. Flow %
-8,663.77%
Top 10 Hldgs %
100%
Holding
5
New
2
Increased
–
Reduced
–
Closed
3

Top Buys

Rank Stock Value
1
MRSN
Mersana Therapeutics
MRSN
+$903K
2
QTRX icon
Quanterix
QTRX
+$188K

Top Sells

Rank Stock Value
1
DT icon
Dynatrace
DT
+$106M
2
DDOG icon
Datadog
DDOG
+$5.67M
3
PHR icon
Phreesia
PHR
+$286K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRSN
1
DELISTED
Mersana Therapeutics
MRSN
$1.08M 84.38%
+1,624
New +$903K
QTRX icon
2
Quanterix
QTRX
$180M
$200K 15.63%
+4,300
New +$188K
DDOG icon
3
Datadog
DDOG
$81.6B
– –
-55,511
Closed -$5.67M
DT icon
4
Dynatrace
DT
$14.1B
– –
-2,584,828
Closed -$106M
PHR icon
5
Phreesia
PHR
$706M
– –
-8,904
Closed -$286K

Similar funds

BH
Broadfin Holdings Melville, New York $23.5M AUM
BCM
BCK Capital Management Stamford, Connecticut $23M AUM 32.69% 1-Year Est. Return
SA
Strategic Advocates Logan, Utah $22.6M AUM 26.98% 1-Year Est. Return
CG
Covalis (Gibraltar) Midtown, Gibraltar $22.5M AUM 9.5% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
BAM
BTS Asset Management Lincoln, Massachusetts $25.9M AUM 2.16% 1-Year Est. Return
IW
Imprint Wealth Mount Pleasant, South Carolina $21.9M AUM
SPC
Stone Point Capital Greenwich, Connecticut $21.9M AUM 47.18% 1-Year Est. Return

Pathway Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Pathway Capital Management held 5 positions worth $1.28M, down 99% from $112M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Pathway Capital Management withdrew a net $111M in Q4 2020, closing 3 positions. Its most notable exit was Dynatrace, an estimated $106M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 0.26% a quarter earlier, followed by Technology.

Against the trend, Pathway Capital Management opened a new position in Mersana Therapeutics worth $1.08M.

  • Pathway Capital Management's largest Q4 2020 buy was Mersana Therapeutics: 1,624 shares worth $1.08M.
  • Pathway Capital Management fully exited Dynatrace in Q4 2020, selling an estimated $106M.
  • Pathway Capital Management's ten largest holdings make up 100% of its $1.28M portfolio in Q4 2020.
  • Pathway Capital Management opened 2 new positions and closed 3 in Q4 2020.
  • Pathway Capital Management's portfolio value fell 99% quarter-over-quarter to $1.28M.

Based on Pathway Capital Management's 13F filing for Q4 2020, filed 10 Feb 2021.